Fig. 3

TMα abolishes oxaliplatin (OHP)-induced neuropathic allodynia in rodents. a–c Preventive (a, b) and therapeutic (c) effects of TMα on the peripheral neuropathy caused by i.p. administration of OHP at 5 mg/kg in mice. To evaluate the preventive effect, TMα at 1 or 10 mg/kg was administered i.p. once 1 h before OHP treatment (a) or three times 1 h before and 5 h and 2 days after OHP treatment (b). To examine the therapeutic effect, TMα at 0.1, 1, or 3 mg/kg was administered i.p. 8 days after OHP treatment (c). d Preventive effect of TMα on the mechanical hyperalgesia (paw pressure test) and allodynia (von Frey test) caused by four repeated i.p. administrations of OHP at 5 mg/kg on days 0, 3, 6, and 9 in rats. TMα at 1 or 3 mg/kg was administered i.p. on days 0, 1, 3, 4, 6, 7, 9, and 10 of OHP treatment. V, vehicle. Data show the mean with SEM for four to eight (a), five to six (b), and four to six (c) mice and for five rats (d). *P < 0.05, **P < 0.01 vs. vehicle + vehicle; ^†P < 0.05, ^††P < 0.01 vs. vehicle + OHP